Considering their rapid and sustained clinical advantages, the current guideline recommends administration of high-intensity statins in patients with acute myocardial infarction (AMI) for secondary prevention. Statins typically prevent cardiovascular events by lowering total and low-density lipoprotein (LDL) cholesterol levels in the serum. ConclusionsĪdministering high-intensity atorvastatin and rosuvastatin in patients with AMI produced comparable effects on NODM and clinical outcomes, suggesting their clinical equivalence in secondary prevention.
Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE. The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. Event-free survival rate of NODM was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. Resultsīaseline characteristics were comparable between the two groups. The atorvastatin and rosuvastatin groups were evaluated for the incidence of NODM and major adverse cardiac events (MACE) including death, myocardial infarction, and revascularization cases in the following 3 years. Among them, 2221 patients without diabetes who had been administered with high-intensity atorvastatin (40–80 mg) and rosuvastatin (20 mg) were investigated. Methodsĭata from the Korea Acute Myocardial Infarction Registry were collected from November 2011 to October 2015, and 13,104 patients with AMI were enrolled from major cardiovascular centers. We investigated the effect of high-intensity atorvastatin and rosuvastatin on new-onset diabetes mellitus (NODM) and cardiovascular outcomes over a 3-year follow-up period. However, there have been consistent concerns regarding its association with diabetes mellitus. If this question would have been "Rank the following statins in order from lowest to highest dose required to achieve equivalent LDL lowering" then the order would be reversed because Crestor due to its highest potency would require the lowest dose to achieve LDL lowering.High-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. Be sure and understand exactly what the question is asking. Ranking question are inherently subject to mistakes in selecting the correct order. High "potent" or intensity statins are recommended for the highest cardiovascular risk groups in order to decrease their risk of morbidity and mortality. Rosuvastatin is the most potent statin followed by atorvastatin, simvastatin, and pravastatin at equivalent doses.
Typically statins are recommended in a number of groups and discussed as "intensity" rather than potency but essentially this is the same idea. HMG-CoA reductase inhibitors (statins) are some of the most prescribed agents in medicine due to their beneficial effects on cholesterol and more importantly outcomes such as nonfatal MI, stroke, and overall mortality. Rank the following HMG-CoA reductase inhibitors effects on LDL cholesterol from least to most potent. During clinic one afternoon an internal medicine resident inquires of you regarding relative potency of various HMG-CoA reductase inhibitors and LDL cholesterol lowering. You are an internal medicine clinic pharmacist practicing at the VA medical center.